Eli Lilly and Company (NYSE:LLY – Get Free Report)’s share price fell 2.5% on Tuesday . The stock traded as low as $1,190.20 and last traded at $1,199.30. Approximately 3,700,387 shares traded hands during mid-day trading, an increase of 14% from the average session volume of 3,241,918 shares. The stock had previously closed at $1,229.93.
Key Stories Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: The FDA selected Lilly for its PreCheck pilot program, which is designed to speed reviews of new U.S. manufacturing facilities and could help support Lilly’s large expansion plans. Article Title
- Positive Sentiment: Analysts and market commentary continue to highlight Lilly’s growth beyond GLP-1 drugs, pointing to new launches and label expansions that could broaden revenue over time. Article Title
Wall Street Analysts Forecast Growth
LLY has been the subject of several research analyst reports. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Rothschild & Co Redburn upped their target price on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Berenberg Bank raised their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price objective for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,235.07.
Eli Lilly and Company Stock Performance
The company has a 50 day simple moving average of $1,042.73 and a 200-day simple moving average of $1,022.85. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market cap of $1.13 trillion, a P/E ratio of 42.60, a price-to-earnings-growth ratio of 1.32 and a beta of 0.53.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.
Institutional Investors Weigh In On Eli Lilly and Company
A number of hedge funds have recently made changes to their positions in the business. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth $25,000. Osbon Capital Management LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $30,000. Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
